Patent US4502143A successfully refreshed from Google Patents.
US4469677A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptide active immunosuppressant fraction
Assignee: Individual
•
Filing: 1982-06-30
•
Granted: 1984-09-04
•
Expires: 2002-06-30
Abstract
Abstract Immunosuppressive polypeptide fractions prepared by enzymatic digestion of specific allergens are non-reactive in animals and humans and effective by parenteral administration, the immunosuppression being antigen specific, affecting production of immunoglobulins. A method of producing immunosuppressive polypeptide fractions and a method of desensitizing mammals therewith are disclosed.
Inventors
- 👤 J. Gabriel Michael
- 👤 Amadeo J. Pesce
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 16:52
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/35; A61K39/36; Y; Y10; Y10S; Y10S530/00; Y10S530/855; Y10S530/856
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
107 words
An allergen desensitizing polypeptide fraction derived by proteolytic enzymatic digestion from a specific globular protein allergen causing the allergic reaction to be treated, said allergen being a native pollen or insect venom containing phospholipase A, said fraction consisting essentially of a degraded polypeptide having a molecular weight of less than about 10,000, a nominal molecular radius not greater than about 15 angstroms, an inability to precipitate with specific antibodies, an inability to induce substantial passive cutaneous anaphylaxis reaction in a sensitized mammal, an inability to release histamine from sensitized mast cells or basophils, an inability to induce substantial antibody response, and a capability of inducing antigen-specific suppression.
Claim 2
Dependent Claim
107 words
An allergen desensitizing polypeptide fraction derived by proteolytic enzymatic digestion from a specific globular protein allergen causing the allergic reaction to be treated, said allergen being a native pollen or insect venom containing phospholipase A, said fraction consisting essentially of a degraded polypeptide having a molecular weight of less than about 10,000, a nominal molecular radius not greater than about 15 angstroms, an inability to precipitate with specific antibodies, an inability to induce substantial passive cutaneous anaphylaxis reaction in a sensitized mammal, an inability to release histamine from sensitized mast cells or basophils, an inability to induce substantial antibody response, and a capability of inducing antigen-specific suppression.
Claim 3
Dependent Claim
30 words
The allergen desensitizing polypeptide fraction claimed in claim 1, wherein said native pollen is ragweed pollen, and wherein the molecular weight of said fraction is not less than about 2,000.
Claim 4
Independent Claim
125 words
A method of producing an allergen desensitizing polypeptide fraction which comprises subjecting an aqueous extract of a native globular protein allergen to digestion by a proteolytic enzyme, said allergen being a native pollen or insect venom containing phospholipase A, controlling the digestion time and conditions and separating residual reactive product after said proteolytic digestion, thereby obtaining a final reaction product consisting essentially of a degraded polypeptide fraction having a molecular weight of less than about 10,000 and a nominal molecular radius not greater than about 15 angstroms, said degraded polypeptide fraction exhibiting an inability to precipitate with specific antibodies, an inability to induce substantial passive cutaneous anaphylaxis in a sensitized mammal, an inability to induce substantial antibody response, and a capability of inducing antigen-specific suppression.
Claim 5
Independent Claim
125 words
A method of producing an allergen desensitizing polypeptide fraction which comprises subjecting an aqueous extract of a native globular protein allergen to digestion by a proteolytic enzyme, said allergen being a native pollen or insect venom containing phospholipase A, controlling the digestion time and conditions and separating residual reactive product after said proteolytic digestion, thereby obtaining a final reaction product consisting essentially of a degraded polypeptide fraction having a molecular weight of less than about 10,000 and a nominal molecular radius not greater than about 15 angstroms, said degraded polypeptide fraction exhibiting an inability to precipitate with specific antibodies, an inability to induce substantial passive cutaneous anaphylaxis in a sensitized mammal, an inability to induce substantial antibody response, and a capability of inducing antigen-specific suppression.
Claim 6
Dependent Claim
20 words
The method claimed in claim 3, wherein said enzyme is carboxypeptidase A, trypsin, chymotrypsin, papain, bacterial protease, nagarase, or pepsin.
Claim 7
Dependent Claim
33 words
The method claimed in claim 3, wherein said step of separating residual reactive allergen comprises detoxifying said reaction product by molecular exclusion chromatography, molecular filtration, or affinity absorption of said residual reactive antigens.
Claim 8
Dependent Claim
19 words
The method claimed in claim 3, wherein said allergen is ragweed pollen and said enzyme is nagarase or pepsin.
Claim 9
Dependent Claim
19 words
The method claimed in claim 3, wherein said allergen is insect venom phospholipase A and said enzyme is pepsin.
Claim 10
Independent Claim
100 words
A method of desensitizing a mammal against allergic reaction, which comprises administering to an atopic mammal, prior to or after exposure to an antigen, a dosage of a polypeptide fraction derived by proteolytic enzymatic digestion from a specific globular protein allergen causing said allergic reaction in an amount effective to inhibit significantly immunological reactions without inducing anaphylaxis in said mammal, said allergen being a native pollen or insect venom containing phospholipase A, said fraction consisting essentially of a degraded polypeptide having a molecular weight of less than about 10,000, and a nominal molecular radius not greater than about 15 angstroms.
Claim 11
Independent Claim
100 words
A method of desensitizing a mammal against allergic reaction, which comprises administering to an atopic mammal, prior to or after exposure to an antigen, a dosage of a polypeptide fraction derived by proteolytic enzymatic digestion from a specific globular protein allergen causing said allergic reaction in an amount effective to inhibit significantly immunological reactions without inducing anaphylaxis in said mammal, said allergen being a native pollen or insect venom containing phospholipase A, said fraction consisting essentially of a degraded polypeptide having a molecular weight of less than about 10,000, and a nominal molecular radius not greater than about 15 angstroms.
Claim 12
Dependent Claim
18 words
The method claimed in claim 8, wherein said specific globular protein allergen is insect venom containing phospholipase A.
Claim 13
Dependent Claim
13 words
The method claimed in claim 9, wherein said specific allergen is ragweed pollen.
Claim 14
Dependent Claim
13 words
The method claimed in claim 8, wherein said polypeptide fraction is administered parenterally.
Claim 15
Dependent Claim
19 words
The method claimed in claim 8, which comprises administering to an atopic mammal the polypeptide fraction of claim 1.
Claim 16
Dependent Claim
19 words
The allergen desensitizing polypeptide fraction claimed in claim 1, wherein said specific allergen is insect venom containing phospholiphase A.
References Cited (Backward Citations)
US4158705A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-04 | 1988-03-05 | 1988-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-04 | 1992-03-05 | 1992-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-04 | 1996-03-05 | 1996-09-04 | $7700.00 | Window Closed / Lapsed |